According to the Zhitong Finance App, Zejing Pharmaceutical (688266.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1.05 billion yuan, an increase of 220.88%; net profit attributable to shareholders of listed companies was 640 million yuan, which turned a year-on-year loss into a profit; deducted non-net profit of 617 million yuan, which turned a year-on-year loss into a profit; and basic earnings per share were 2.42 yuan.

According to the Zhitong Finance App, Zejing Pharmaceutical (688266.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1.05 billion yuan, an increase of 220.88%; net profit attributable to shareholders of listed companies was 640 million yuan, which turned a year-on-year loss into a profit; deducted non-net profit of 617 million yuan, which turned a year-on-year loss into a profit; and basic earnings per share were 2.42 yuan.